These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 11926821)

  • 1. Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism.
    Volles MJ; Lansbury PT
    Biochemistry; 2002 Apr; 41(14):4595-602. PubMed ID: 11926821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils.
    Lashuel HA; Petre BM; Wall J; Simon M; Nowak RJ; Walz T; Lansbury PT
    J Mol Biol; 2002 Oct; 322(5):1089-102. PubMed ID: 12367530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease.
    Volles MJ; Lee SJ; Rochet JC; Shtilerman MD; Ding TT; Kessler JC; Lansbury PT
    Biochemistry; 2001 Jul; 40(26):7812-9. PubMed ID: 11425308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein.
    Li J; Uversky VN; Fink AL
    Biochemistry; 2001 Sep; 40(38):11604-13. PubMed ID: 11560511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation.
    Narhi L; Wood SJ; Steavenson S; Jiang Y; Wu GM; Anafi D; Kaufman SA; Martin F; Sitney K; Denis P; Louis JC; Wypych J; Biere AL; Citron M
    J Biol Chem; 1999 Apr; 274(14):9843-6. PubMed ID: 10092675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defective membrane interactions of familial Parkinson's disease mutant A30P alpha-synuclein.
    Jo E; Fuller N; Rand RP; St George-Hyslop P; Fraser PE
    J Mol Biol; 2002 Jan; 315(4):799-807. PubMed ID: 11812148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy.
    Conway KA; Lee SJ; Rochet JC; Ding TT; Williamson RE; Lansbury PT
    Proc Natl Acad Sci U S A; 2000 Jan; 97(2):571-6. PubMed ID: 10639120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease.
    Conway KA; Harper JD; Lansbury PT
    Nat Med; 1998 Nov; 4(11):1318-20. PubMed ID: 9809558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations in the lipid-binding domain of alpha-synuclein confer overlapping, yet distinct, functional properties in the regulation of dopamine transporter activity.
    Wersinger C; Prou D; Vernier P; Niznik HB; Sidhu A
    Mol Cell Neurosci; 2003 Sep; 24(1):91-105. PubMed ID: 14550771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease.
    Park JY; Lansbury PT
    Biochemistry; 2003 Apr; 42(13):3696-700. PubMed ID: 12667059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation E46K increases phospholipid binding and assembly into filaments of human alpha-synuclein.
    Choi W; Zibaee S; Jakes R; Serpell LC; Davletov B; Crowther RA; Goedert M
    FEBS Lett; 2004 Oct; 576(3):363-8. PubMed ID: 15498564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation.
    Jensen PH; Nielsen MS; Jakes R; Dotti CG; Goedert M
    J Biol Chem; 1998 Oct; 273(41):26292-4. PubMed ID: 9756856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease.
    Volles MJ; Lansbury PT
    Biochemistry; 2003 Jul; 42(26):7871-8. PubMed ID: 12834338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Parkinson's disease-linked mutations on the structure of lipid-associated alpha-synuclein.
    Bussell R; Eliezer D
    Biochemistry; 2004 Apr; 43(16):4810-8. PubMed ID: 15096050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oligomers of Parkinson's Disease-Related α-Synuclein Mutants Have Similar Structures but Distinctive Membrane Permeabilization Properties.
    Stefanovic AN; Lindhoud S; Semerdzhiev SA; Claessens MM; Subramaniam V
    Biochemistry; 2015 May; 54(20):3142-50. PubMed ID: 25909158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes.
    Ding TT; Lee SJ; Rochet JC; Lansbury PT
    Biochemistry; 2002 Aug; 41(32):10209-17. PubMed ID: 12162735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha -synuclein in human and transgenic mouse brain.
    Kahle PJ; Neumann M; Ozmen L; Muller V; Jacobsen H; Schindzielorz A; Okochi M; Leimer U; van Der Putten H; Probst A; Kremmer E; Kretzschmar HA; Haass C
    J Neurosci; 2000 Sep; 20(17):6365-73. PubMed ID: 10964942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease.
    Wood SJ; Wypych J; Steavenson S; Louis JC; Citron M; Biere AL
    J Biol Chem; 1999 Jul; 274(28):19509-12. PubMed ID: 10391881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice.
    Lee MK; Stirling W; Xu Y; Xu X; Qui D; Mandir AS; Dawson TM; Copeland NG; Jenkins NA; Price DL
    Proc Natl Acad Sci U S A; 2002 Jun; 99(13):8968-73. PubMed ID: 12084935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease.
    Rochet JC; Outeiro TF; Conway KA; Ding TT; Volles MJ; Lashuel HA; Bieganski RM; Lindquist SL; Lansbury PT
    J Mol Neurosci; 2004; 23(1-2):23-34. PubMed ID: 15126689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.